Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz Enters Canada With First Denosumab Biosimilar

Jubbonti Is Canada’s First and Only Denosumab Biosimilar For Osteoporosis

Executive Summary

Sandoz has truly established its position as the frontrunner in the denosumab race after a Canadian approval, but the path to the US market has been hindered by a lawsuit from the originator Amgen.

You may also be interested in...

Sandoz Maintains Lead On Denosumab With First EU Recommendations

Sandoz has again demonstrated its clout in the biosimilars space, taking a major step towards obtaining pan-European marketing authorizations for its biosimilar Prolia/Xgeva products.

Sandoz Benefits From Betting Big On Biosimilars

Sandoz’s biosimilars business was a big earner for the company in 2023. During the firm’s Q4 results call, CEO Richard Saynor provided a detailed breakdown of key products in the biosimilars portfolio and pipeline, as he highlighted sales growth of 26% in the most recent quarter.

Sandoz Gets US Denosumab Approvals – But When Will They Launch?

Sandoz has received the first FDA approvals for denosumab biosimilar rivals to Prolia and Xgeva under the names Wyost and Jubbonti. However, the firm has declined to comment on launch details while it remains locked in litigation with originator Amgen.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts